FRIEDMAN PAUL A
Transaction: 06/09/2026
BUY
Change
+38,000
Price
$3.94
Filing
06/10/2026
Type
BUY
Prelude Therapeutics Incorporated
PRLD • Biotechnology
$5.46
▲ +0.21 (+4.00%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$537.20M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 70.8%Manageable debt level · 0.26Healthy liquidity · 1.99Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:56 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$5.46
Change4.00%
Shares Out98.39M
Market Cap$537.20M
Enterprise Value$403.09M
52W Range0.82 - 5.91
Beta0.95
P/E-8.88
P/S23.96
P/B4.02
P/FCF-16.15
EV/Sales17.98
Price$5.46
Change4.00%
Shares Out98.39M
Market Cap$537.20M
Enterprise Value$403.09M
52W Range0.82 - 5.91
Beta0.95
P/E-8.88
P/S23.96
P/B4.02
P/FCF-16.15
EV/Sales17.98
EV/EBITDA-6.27
EV/FCF-12.12
Earnings Yield-11.26%
FCF Yield-6.19%
Dividend Yield0.00%
Gross Margin85.91%
Oper. Margin-8.61%
Profit Margin-8.20%
Debt/Eq0.26
Current Ratio1.99
Quick Ratio1.99
Target$8.00
Target Upside46.52%
Target Median$8.00
Target Range8.00 - 8.00
Volume888.07K
Avg Volume440.41K
EPS Surprise0.14
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
48/100
Why this score▼
Positive revenue growth · 70.8%Manageable debt level · 0.26Healthy liquidity · 1.99Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 8 analyst votes · 2026-09-05
69/100
Neutral
Bullish
5
Hold
1
Bearish
2
Price Target
2026-08-14
Low
$8.00
Mean
$8.00
Median
$8.00
High
$8.00
Insider Transactions
Recent executive and insider activity
⚠ 1 high-volume insider sell detected
Sandor Victor
Transaction: 06/09/2026
BUY
Change
+38,000
Price
$3.94
Filing
06/10/2026
Type
BUY
Bonita David P
Transaction: 06/09/2026
BUY
Change
+38,000
Price
$3.94
Filing
06/10/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| FRIEDMAN PAUL A | BUY | +38,000 | $3.94 | 06/09/2026 | 06/10/2026 |
| Sandor Victor | BUY | +38,000 | $3.94 | 06/09/2026 | 06/10/2026 |
| Bonita David P | BUY | +38,000 | $3.94 | 06/09/2026 | 06/10/2026 |
| Babler Martin | BUY | +38,000 | $3.94 | 06/09/2026 | 06/10/2026 |
| Dorton Katina | BUY | +38,000 | $3.94 | 06/09/2026 | 06/10/2026 |
| BAKER BROS. ADVISORS LP | BUY | +38,000 | $3.94 | 06/09/2026 | 06/10/2026 |
| Morris Charles Q | BUY | +450,000 | $4.70 | 05/01/2026 | 05/04/2026 |
| RA CAPITAL MANAGEMENT, L.P. | BUY | +1,407,000 | $0.00 | 04/27/2026 | 04/28/2026 |
| RA CAPITAL MANAGEMENT, L.P. | SELL | -1,407,000 | $0.00 | 04/27/2026 | 04/28/2026 |
| RA CAPITAL MANAGEMENT, L.P. | OTHER | 0 | Not reported | 04/21/2026 | 04/28/2026 |
| ORBIMED ADVISORS LLC | BUY | +1,126,126 | $4.44 | 04/21/2026 | 04/23/2026 |
| Bonita David P | BUY | +1,126,126 | $4.44 | 04/21/2026 | 04/23/2026 |
| BAKER BROS. ADVISORS LP | BUY | +114,601 | $0.00 | 04/21/2026 | 04/22/2026 |
| Morris Charles Q | OTHER | 0 | Not reported | 04/15/2026 | 04/15/2026 |
| Brusky Sean P. | OTHER | +275,000 | Not reported | 03/05/2026 | 03/19/2026 |
| Brusky Sean P. | OTHER | 0 | Not reported | 03/05/2026 | 03/19/2026 |
| Vaddi Krishna | BUY | +837,000 | $2.30 | 02/04/2026 | 02/05/2026 |
| Lim Bryant David | BUY | +275,000 | $2.30 | 02/04/2026 | 02/05/2026 |
| Scherle Peggy | BUY | +230,000 | $2.30 | 02/04/2026 | 02/05/2026 |
| Combs Andrew | BUY | +230,000 | $2.30 | 02/04/2026 | 02/05/2026 |